Optimistic Buy Rating for Cullinan Management Driven by Promising Drug Pipeline and Upcoming Catalysts
I'm PortAI, I can summarize articles.
Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating for Cullinan Management, raising the price target to $26 due to promising drug pipeline developments and upcoming catalysts. The company, in collaboration with Taiho Oncology, is advancing a New Drug Application for zipalertinib, supported by positive trial results. Upcoming catalysts include Phase 1 results for CLN-049. Despite potential risks, the outlook remains optimistic. JonesTrading also maintained a Buy rating with a $34 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments